Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease

European Journal of Pharmacology

Volumn 764, Issue , 2015, Pages 571-581

  Kalra, Jaspreet ^a,b   Khan, Aamir ^b  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

Alzheimer's disease; Amyloid beta; Herbal supplements; Miscellaneous therapies; Physical work and exercise; Tau phosphorylation

Indexed keywords

ALPHA SECRETASE MODULATOR; AMYLOID BETA PROTEIN; BETA SECRETASE INHIBITOR; CENTRAL NERVOUS SYSTEM AGENTS; CHELATING AGENT; CURCUMA LONGA EXTRACT; GAMMA SECRETASE INHIBITOR; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULINASE; MELATONIN; MEMBRANE METALLOENDOPEPTIDASE; PROTEIN INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; MAPT PROTEIN, HUMAN; PLANT MEDICINAL PRODUCT; PROTEIN AGGREGATE;

AGNOSIA; ALZHEIMER DISEASE; APHASIA; APRAXIA; ARTICLE; BEHAVIOR DISORDER; CURCUMA LONGA; DRUG EFFICACY; EMOTIONAL DISORDER; ENZYME ACTIVITY; EXERCISE; GINKGO BILOBA; GINSENG; HUMAN; HUMAN RELATION; IMMUNOTHERAPY; MEMORY DISORDER; MICROTUBULE; MOOD DISORDER; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PSYCHOPATHY; SENILE PLAQUE; SOCIAL DISABILITY; SYMPTOM; WITHANIA SOMNIFERA; AFFECT; ANIMAL; BRAIN; COGNITION; DRUG DEVELOPMENT; DRUG EFFECTS; KINESIOTHERAPY; MEMORY; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROCEDURES; PROTEINOSIS; PSYCHOLOGY;

AFFECT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; COGNITION; DRUG DISCOVERY; EXERCISE THERAPY; HUMANS; MEMORY; MOTOR ACTIVITY; PHOSPHORYLATION; PLANT PREPARATIONS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS;

EID: 84938630567     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.07.043     Document Type: Review

References (148)

1. A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde Allg. Z. Psychiatr. 64 1907 146 148
2. S. Akhondzadeh, and S.H. Abbasi Herbal medicine in the treatment of Alzheimer's disease Am. J. Alzheimer's Dis. Other Dement. 21 2006 113 118
3. R. Anand, K.D. Gill, and A.A. Mahdi Therapeutics of Alzheimer's disease: past, present and future Neuropharmacology 76 2014 27 50
4. C. Arcoverde, and et al. Treadmill training as an augmentation treatment for Alzheimers disease: a pilot randomized controlled study Arq. Neuropsiquiatr. 72 2014 190 196
5. H. Atamna, and et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways FASEB J. 22 2008 703 712
6. R.C. Barber The genetics of Alzheimer's disease Scientifica 2012 2012 Article ID 24621, 14 pp.
7. K.J. Barnaham, and et al. Metals in Alzheimer's and Parkinson's diseases Curr. Opin. Chem. Biol. 12 2008 222 228
8. R.T. Bartus, and et al. The cholinergic hpothesis of geriatric memory dysfunction Science 217 1982 408 417
9. R.J. Bateman, and et al. A gamma secretase inhibitor decreases amyloid-beta production in the central nervous system Ann. Neurol. 66 2009 48 54
10. N.D. Belyaev, and et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease EMBO Rep. 10 2009 94 100
11. F. Benedetti, and et al. Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder Neuropsychopharmacology 38 2013 313 327
12. D.L. Brody, and D.M. Holtzman Active and passive immunotherapy for neurodegenerative disorders Annu. Rev. Neurosci. 31 2008 175 193
13. K.R. Brunden, and et al. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy J. Neurosci. 41 2010 13861 13866
14. K.R. Brunden, and et al. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies Pharmacol. Res. 63 2011 341 351
15. A. Caccamo, and et al. Age- and region-dependent alterations in Abeta degrading enzymes: implications for Abeta-induced disorders Neurobiol. Aging 26 2005 645 654
16. C. Caltagirone, and et al. The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review Aging Clin. Exp. Res. 24 2012 580 587
17. F. Chen, E.A. Eckman, and C.B. Eckman Reductions in levels of the Alzheimer's amyloid beta peptide after oral administration of ginsenosides FASEB J. 20 2006 1269 1271
18. R.A. Cherny, and et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β amyloid deposition in Alzheimer's disease: transgenic mice Neuron 2001 665 676
19. M. Citron Alzheimer's disease: strategies for disease modification Nat. Rev. Drug Discov. 9 2010 387 398
20. G.M. Cole, and et al. Neuroprotective effects of curcumin Adv. Exp. Med. Biol. 595 2007 197 212
21. E.E. Congdon, and et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo Autophagy 8 2012 609 622
22. L. Crews, and E. Masliah Molecular mechanisms of neurodegeneration in Alzheimer's disease Hum. Mol. Genet. 19 2010 R12 R20
23. P.J. Crouch, and K.J. Barnham. Therapeutic redistribution of metal ions to treat Alzheimer's disease Acc. Chem. Res. 45 2012 1604 1611
24. W.P. Chang, and et al. β Secretase inhibitor GRL8234 rescues age related cognitive decline in APP transgenic mice FASEB J. 25 2011 775 784
25. L.F. Defina, and et al. The association between midlife cardio respiratory fitness levels and later-life dementia: a cohort study Ann. Intern. Med. 158 2013 162 168
26. Y.Q. Deng, and et al. Effects of melatonin on wortmannin-induced tau hyperphosphorylation Acta Pharmacol. Sin. 26 2005 519 526
27. L. Devi, and M. Ohno Mechanisms that lessen benefits of β-secretase reduction in a mouse model of Alzheimer's disease Transl. Psychiatry 3 2013 e284 10.1038/tp.2013.59
28. J. Dill, and et al. Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS J. Neurosci. 28 2008 8914 8928
29. J.C. Dodart, and et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model Nat. Neurosci. 5 2002 452 457
30. G. Donmez, and et al. SIRT1 suppresses beta amyloid production by activating the alpha-secretase gene ADAM10 Cell 142 2010 320 332
31. T. Engel, and et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J. Neurochem. 99 2006 1445 1455
32. L. Ereshefsky, and et al. The role of CSF dynabridging studies in developing new therapies for Alzheimer's disease Alzheimer's Dement. 5 2009 414 415
33. S.A. Eshkoor, and et al. The effects of sleep quality, physical activity, and environmental quality on the risk of falls in dementia Am. J. Alzheimer's Dis. Other Dement. 28 2013 403 407
34. M.R. Farlow, and et al. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations Dement. Geriatr. Cogn. Disord. 5 2008 408 422
35. I. Ferrer, and et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease Brain Pathol. 14 2004 11 20
36. M.E. Frazer, and et al. Reduced pathology and improved behavioral performance in alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-β and interleukin-4 Mol. Ther. 16 5 2008 845 853
37. J. Geng, and et al. Ginseng for cognition Cochrane Database Syst. Rev. 12 2010 CD007769
38. A.K. Ghosh, M. Brindisi, and J. Tang Developing β secretase inhibitors for treatment of Alzheimer's disease J. Neurochem. 120 2012 71 83
39. A.K. Ghosh, and H.L. Osswald BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease Chem. Soc. Rev. 43 19 2014 6765 6813
40. S. Gilman, M. Koller, and R.S. Black Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial Neurology 64 2005 1553 1562
41. C. Giommarelli, and et al. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition Cell. Mol. Life Sci. 67 2010 995 1004
42. I. Gozes, I. Divinsk, and I. Piltzer. NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42) B.M.C. Neurosci. 9 2008 S3
43. I. Gozes NAP (davunetide) provides functional and structural neuroprotection Curr. Pharm. Des. 17 2011 1040 1044
44. J.T. Greenamyre, and et al. Glutamate transmission and toicity in Alzheimer's disease Prog. Neuro-Psych. Biol. Psychiatry 12 1988 421 430
45. H.H. Griffiths, and et al. Emerging and potential therapies for Alzheimer's disease Expert Opin. Ther. Targets 12 2008 693 704
46. T. Grimmer, and A. Kurz Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review Drugs Aging. 12 2006 957 967
47. M.O. Grimm, and et al. Neprilysin and Ab clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer's disease Front. Aging Neurosci. 23 2013 98
48. H. Grossman, and et al. NIC5-15 as a treatment for Alzheimer's: safety, pharmacokinetics and clinical variables Alzheimer's Dement. 5 2009 259
49. H. Hampel, and et al. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future Expert Rev. Neurother. 15 2015 83 105
50. H. Hampel, and et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study J. Clin. Psychiatry 70 2009 922 931
51. Han, M. et al., 2010. Preparation of small molecule compounds for promoting stem cells hyperplasia. P.C.T Int. Appl. 41 pp. WO 2010130063, A1 20101118, CAN 153:643462
52. H. Hara, and et al. Development of a safe oral Aβ vaccine using recombinant adeno-associated virus vector for Alzheimer's disease J. Alzheimer's Dis. 6 2004 483 488
53. J.A. Hardy, and G.A. Higgins. Alzheimer's disease: the amyloid cascade hypothesis Science 256 1992 184 185
54. M. Haupt, A. Karger., and M. Janner. Improvement of agitation and anxiety in demented patients after psychoeducative group intervention with their caregivers Int. J. Geriatr. Psychiatry 2000 1125 1129
55. C.A. Hawkes, and et al. Small molecule inhibitors of A beta-aggregation and neurotoxicity. Drug Dev. Res. 70, 111-124.icro-PET imaging Acta Pharmacol. Sin. 29 2009 548 554
56. D.B. Henley, and et al. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease Exp. Opin. Pharmacother. 10 2009 1657 1664
57. P. Heyn, B.C. Abreu, and K.J. Ottenbacher The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis Arch. Phys. Med. Rehabil. 85 2004 1694 1704
58. C. Holmes, and et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo controlled phase I trial Lancet 372 2008 216 223
59. D.M. Holtzman, J.C. Morris, and A.M. Goate Alzheimer's disease: the challenge of the second century Sci. Transl. Med. 3 2011 77sr1
60. C.R. Hopkins Molecule spotlight on BMS-708163 ACS Chem. Neurosci. 5 2012 149 150
61. S. Hu, and et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals Neurobiol. Dis. 33 2009 193 206
62. Humanetics Pharmaceuticals, 2009. A disease modifying drug candidate for Alzheimer's disease. NIC515. Available at: (accessed 08.07.09).
63. S.H. Hwang, and et al. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: involvement of non-amyloidogenic processing J. Alzheimer's Dis. 31 2012 207 223
64. B.P. Imbimbo, and et al. CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease J. Alzheimer's Dis. 20 2010 159 173
65. J.S. Jacobsen, and et al. Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade Proc. Natl. Acad. Sci. USA 105 2008 8754 8759
66. S. Jacobsen, and et al. GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease Alzheimer's Dement. 5 2009 139
67. R. Jakob-Roetne, and H. Jacobsen Alzheimer's disease: from pathology to therapeutic approaches Angew. Chem. Int. Ed. 48 2009 3030 3059
68. M. Janusz, and A. Zabłocka Colostral proline-rich polypeptides - immunoregulatory properties and prospects of therapeutic use in Alzheimer's disease Curr. Alzheimer. Res. 7 2010 323 333
69. J. Kalra, and et al. Cerebroprotective effects of RAS inhibitors: beyond their cardio-renal actions J. Renin Angiotensin Aldosterone Syst. 2015 [Epub ahead of print]
70. V.B. Kenche, and K.J. Barnham Alzheimer's disease and metals: therapeutic opportunities Br. J. Pharmacol. 163 2011 1476 5381
71. D.H. Kim, and et al. Ginsenoside Rd inhibits the expressions of iNOS and COX-2 by suppressing NF-κB in LPS-stimulated RAW264.7 cells and mouse liver J. Ginseng Res. 37 2013 54 63
72. T. Kuboyama, C. Tohda, and K. Komatsu Neuritic regeneration and synaptic reconstruction induced by withanolides. A Br. J. Pharmacol. 144 2005 961 971
73. V. Kumar, and K.D. Gill Oxidative stress and mitochondrial dysfunction in aluminium neurotoxicity and its amelioration: a review Neurotoxicology 41 2014 154 166
74. K.R. Kurapati, and et al. Ashwagandha (Withania somnifera) reverses β-Amyloid1-42 induced toxicity in human neuronal cells: implications in HIV-Associated Neurocognitive Disorders (HAND) PLoS One 8 2013 77624
75. A. Kurz, and R. Perneczky Novel insights for the treatment of Alzheimer's disease Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 373 379
76. G. Landreth, and et al. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease Neurotherapeutics 5 2008 481 489
77. P.L. Le Bars, and et al. Influence of the severity of cognitive Impairment on the effect of the Ginkgo biloba extract EGb 761in Alzheimer's disease Neuropsychobiology 45 2002 19 26
78. M.C. Leal, and et al. Transcriptional regulation of insulin-degrading enzyme modulates mitochondrial amyloid β (Aβ) peptide catabolism and functionality J. Biol. Chem. 288 2013 12920 12931
79. M.D. Ledesma, and et al. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains EMBO Rep. 1 2000 530 535
80. M.S. Lee, and et al. Ginseng for cognitive function in Alzheimer's disease: a systematic review J. Alzheimer's Dis. 18 2009 339 344
81. E.B. Lee, and et al. Targeting Aβ oligomers by passive immunization with a conformation selective monoclonal antibody improves learning and memory in APP transgenic mice J. Biol. Chem. 281 2005 4292 4299
82. S.T. Lee, and et al. Panax ginseng enhances cognitive performance in Alzheimer disease Alzheimer Dis. Assoc. Disord. 22 2008 222 226
83. W.H. Lee, and et al. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century Curr. Neuropharmacol. 11 2013 338 378
84. M.A. Leissring, and et al. Enhanced proteolysis of A-beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death Neuron 40 2003 1087 1093
85. C.A. Lemere Immunotherapy for Alzheimer's disease: hoops and hurdles Mol. Neurodegener. 8 2013 36
86. Y. Levites, and et al. Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model J. Clin. Invest. 116 2006 193 201
87. F. Lezoualc'h, M. Sparapani, and C. Behl N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB J. Pineal Res. 24 1998 168 178
88. G. Liu, and et al. Metal exposure and Alzheimer Pathogenesis J. Struct. Biol. 155 2006 45 51
89. R. Liu, and et al. Cardiorespiratory fitness as a predictor of dementia mortality in men and women Med. Sci. Sports. Exerc. 44 2012 253 259
90. W. Luo, and et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies Proc. Natl. Acad. Sci. USA 104 2007 9511 9516
91. Y. Luo, and et al. Inhibition of amyloid -beta aggregation and caspase -3 activation by the Ginkgo biloba extract EGb761 Proc. Natl. Acad. Sci. USA 99 2002 12197 12202
92. S.A. Mandel, and et al. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG) J. Alzheimer's Dis. 15 2008 211 222
93. I.T. Marsden, and et al. Amyloid-beta-induced amyloid-beta secretion: a possible feed-forward mechanism in Alzheimer's disease J. Alzheimer's Dis. 24 2011 681 691
94. E. Masliah, and et al. A beta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease Neurology 64 2005 129 131
95. M. Mazza, and et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study Eur. J. Neurol. 13 2006 981 985
96. L. McConlogue, and et al. Differential effects of a Rab6 mutant on secretory versus amyloidogenic processing of Alzheimer's beta-amyloid precursor protein J. Biol. Chem. 271 1996 1343 1348
97. Z. Mei, and et al. Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates beta-amyloid deposition through upregulating alpha-secretase in vivo and in vitro Neurosci. Lett. 452 2009 90 95
98. J.S. Miners, P. Kehoe, and S. Love Neprilysin protects against cerebral amyloid angiopathy and Aβ-induced degeneration of cerebrovascular smooth muscle cells Brain. Pathol. 21 2011 594 605
99. S. Mishra, and K. Palanivelu The effect of curcumin (turmeric) on Alzheimer's disease: an overview Ann. Indian Acad. Neurol. 11 2008 13 19
100. Y. Mitani, and et al. Differential Effects between γ Secretase Inhibitors and Modulators on Cognitive Function in Amyloid Precursor Protein Transgenic and Non transgenic Mice J. Neurosci. 32 2012 20372050 10.1523/JNEUROSCI.426411.2012
101. C. Nocjar, M.D. Hammonds, and S.S. Shim Chronic lithium treatment magnifies learning in rats Neuroscience 150 2007 774 788
102. N.N. Nalivaeva, and et al. Effect of sodium valproate administration on brain neprilysin expression and memory in rats J. Mol. Neurosci. 46 2012 569 577
103. M. Necula, and et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization Biochemistry 46 2007 8850 8860
104. J.A. Nicoll, D. Wilkinson, and C. Holmes Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report Nat. Med. 9 2003 448 452
105. C. Niva, and et al. Has inhibition of Aβ production adequately been tested as therapeutic approach in mild AD? A model-based meta-analysis of γ-secretase inhibitor data Eur. J. Clin. Pharmacol. 69 2013 1247 1260
106. W. Noble, and et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. USA 102 2005 6990 6995
107. R. O'Brien, and P. Wong Amyloid precursor protein processing and Alzheimer's disease Annu. Rev. Neurosci. 34 2011 185 204
108. S.M. Ostrowski, and et al. Statins reduce amyloid-beta production through inhibition of protein isoprenylation J. Biol. Chem. 282 2007 26832 26844
109. M.A. Pappolla., and et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: Implications for AD J. Neural. Transm. 107 2000 203 231
110. H. Park, and et al. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β Hum. Mol. Genet. 21 2012 2725 2737
111. R.B. Parsons, and et al. Statins inhibit the dimerization of betasecretase via both isoprenoid- and cholesterol-mediated mechanisms Biochem. J. 399 2006 205 214
112. S. Pietropaolo, and et al. The impact of voluntary exercise on mental health in rodents: a neuroplasticity perspective Behav. Brain Res. 192 2008 42 60
113. R. Postina, and et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model J. Clin. Invest. 113 2004 1456 1464
114. R. Potter, and et al. A systematic review of the effects of physical activity on physical functioning, quality of life and depression in older people with dementia Int. J. Geriatr. Psychiatry 26 2011 1000 1011
115. C. Qiu, M. Kivipelto, and E. Von Strauss. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention Dialogues Clin. Neurosci. 11 2009 111 128
116. R. Raschetti, and et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials PLoS. Med. 11 2007 338
117. B. Reisberg, and et al. Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease N. Engl. J. Med. 348 2003 1333 1341
118. J. Ramirez-Bermudez Alzheimer's disease: critical notes on the history of a medical concept Arch. Med. Res. 43 2012 595 599
119. C.H. Reynolds, and et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3- kinase, phospholipase Cgamma1 Grb2, and Src family kinases J. Biol. Chem. 283 2008 18177 18186
120. J.M. Ringman, and et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study Alzheimer's Res. Ther. 4 2012 43
121. L.E. Rojo, and et al. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease J. Alzheimer's Dis. 19 2010 573 589
122. R.N. Rosenberg Explaining the cause of amyloid burden in Alzheimer disease Arch. Neurol. 59 2002 1367 1368
123. T. Saito, and et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation Nat. Med. 11 2005 434 439
124. N. Scarmeas, and et al. Physical activity and Alzheimer disease course Am. J. Geriatr. Psychiatry 19 2011 471 481
125. D. Schenk, and et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
126. M.L. Selenica, and et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation Br. J. Pharmacol. 152 2007 959 979
127. J.S. Seo, and et al. SK-PC-B70M confers anti-oxidant activity and reduces A beta levels in the brain of Tg2576 mice Brain Res. 1261 2009 100 108
128. A. Serrano-Pozo, and et al. Neuropathological Alterations in Alzheimer disease Cold Spring Harb. Perspect. Med. 1 2011 a006189
129. E.M. Sigurdsson, and et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice Am. J. Pathol. 159 2001 439 447
130. H. Soares, and et al. Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers Alzheimer's Dement. 5 2009 252 253
131. T.L. Spires-Jones, and et al. Tau Pathophysiology in neurodegeneration: a tangled issue Trends Neurosci. 32 2009 150 159
132. G. Stuchbury, and G. Münch Alzheimer's associated inflammation, potential drug targets and future therapies J. Neural. Transm. 112 2005 429 453
133. J. Tang, and et al. Embryonic stem cell-derived neural precursor cells improve memory dysfunction in A beta (1-40) injured rats Neurosci. Res. 62 2008 86 96
134. E. Tsaltas, and et al. Enhancing effects of chronic lithium on memory in the rat Behav. Brain Res. 177 2007 51 60
135. E. Tsaltas, and et al. Lithium and cognitive enhancement: leave it or take it? Psychopharmacology 202 1-3 2008 457 476 10.1007/s00213-008-1311-8
136. D.R. Thal, and et al. Pathology of clinical and preclinical Alzheimer's disease Eur. Arch. Psychiatry Clin. Neurosci. 263 2013 S137 S145
137. J. Tian, and et al. Herbal therapy: a new pathway for the treatment of Alzheimer's disease Alzheimer's Res. Ther. 2 2010 30
138. X. Tian, and et al. The protective effect of hyperbaric oxygen and Ginkgo biloba extract on Aβ25-35-induced oxidative stress and neuronal apoptosis in rats Behav. Brain Res. 242 2013 1 8
139. T. Tomita Secretase inhibitors and modulators for Alzheimer's disease treatment Expert Rev. Neurother. 9 2009 661 679
140. M. Townsend, and et al. Orally available compound prevents deficits in memory caused by the Alzheimer Amyloid-β oligomers Ann. Neurol. 60 2006 668 676
141. R.E. Tractenberg, and et al. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease J. Sleep Res. 12 2003 331 337
142. R.J. Van Marum Current and future therapy in Alzheimer's disease Fundam. Clin. Pharmacol. 22 2008 265 274
143. T. Wisniewski, and F. Goñi Immunotherapy for Alzheimer's disease Biochem. Pharmacol. 88 2014 499 507
144. K.M. Wood, and et al. Efficacy of the novel γ-secretase inhibitor, PF-3084014, in reducing Aβ in brain, CSF, and plasma in guinea pigs and Tg2576 mice Alzheimer's Dement. 4 2008 482
145. Y.H. Wu, and et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease; alterations in preclinical and clinical stages J. Clin. Endocrinol. Metab. 88 2003 5898 5906
146. H.Q. Yang, Z.K. Sun, and S.D. Chen Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau Transl. Neurodegener. 34 2009 528 535
147. R. Yesuvadian, and et al. Potent γ-secretase inhibitors/modulators interact with amyloid-β fibrils but do not inhibit fibrillation: A high-resolution NMR study Biochem. Biophys. Res. Commun. 447 2014 590 595
148. M.Q. Zheng, and et al. Biological characters of [F-18]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging Acta Pharmacol. Sin. 29 2008 548 554